Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMPH NYSEARCA:EPP NYSE:INFA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPHAmphastar Pharmaceuticals$20.16+4.0%$20.05$16.65▼$31.26$854.96M0.91725,604 shs506,257 shsEPPiShares MSCI Pacific ex Japan ETF$53.40+0.5%$55.13$47.62▼$57.07$2.07B0.78468,129 shs597,691 shsINFAInformatica$24.79$24.81$17.61▼$24.98$7.64BN/A3.67 million shsN/AMissed the SpaceX IPO? Buy These 7 Stocks InsteadThe space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPHAmphastar Pharmaceuticals-1.77%+5.27%+2.05%+2.54%-25.39%EPPiShares MSCI Pacific ex Japan ETF-0.04%-3.98%-5.09%-2.78%+7.57%INFAInformatica0.00%0.00%0.00%0.00%+2.69%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPHAmphastar Pharmaceuticals$20.16+4.0%$20.05$16.65▼$31.26$854.96M0.91725,604 shs506,257 shsEPPiShares MSCI Pacific ex Japan ETF$53.40+0.5%$55.13$47.62▼$57.07$2.07B0.78468,129 shs597,691 shsINFAInformatica$24.79$24.81$17.61▼$24.98$7.64BN/A3.67 million shsN/AMissed the SpaceX IPO? Buy These 7 Stocks InsteadThe space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPHAmphastar Pharmaceuticals-1.77%+5.27%+2.05%+2.54%-25.39%EPPiShares MSCI Pacific ex Japan ETF-0.04%-3.98%-5.09%-2.78%+7.57%INFAInformatica0.00%0.00%0.00%0.00%+2.69%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMPHAmphastar Pharmaceuticals 1.88Reduce$24.0019.05% UpsideEPPiShares MSCI Pacific ex Japan ETF 2.79Moderate Buy$53.40N/AINFAInformatica 1.67Reduce$26.004.88% UpsideCurrent Analyst Ratings BreakdownLatest HGEN, INFA, EPP, and AMPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2026AMPHAmphastar Pharmaceuticals BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$23.00 ➝ $20.005/14/2026AMPHAmphastar Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$30.00 ➝ $19.005/11/2026AMPHAmphastar Pharmaceuticals Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$25.00 ➝ $21.005/8/2026AMPHAmphastar Pharmaceuticals Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/21/2026AMPHAmphastar Pharmaceuticals Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold$30.00 ➝ $22.004/10/2026AMPHAmphastar Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)4/8/2026AMPHAmphastar Pharmaceuticals BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$30.00 ➝ $23.00(Data available from 6/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMPHAmphastar Pharmaceuticals$719.89M1.23$4.42 per share4.56$17.17 per share1.17EPPiShares MSCI Pacific ex Japan ETFN/AN/AN/AN/AN/AN/AINFAInformatica$1.64B4.66N/AN/A$6.64 per share3.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMPHAmphastar Pharmaceuticals$98.09M$1.6612.146.883.8111.00%15.12%7.14%8/6/2026 (Estimated)EPPiShares MSCI Pacific ex Japan ETFN/AN/A18.02N/AN/AN/AN/AN/AN/AINFAInformatica$9.93M$0.021,240.1235.93N/A0.62%5.51%2.48%N/ALatest HGEN, INFA, EPP, and AMPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026AMPHAmphastar Pharmaceuticals$0.70$0.42-$0.28$0.14$173.46 million$171.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAMPHAmphastar PharmaceuticalsN/AN/AN/AN/AN/AEPPiShares MSCI Pacific ex Japan ETF$1.903.56%N/AN/AN/AINFAInformaticaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMPHAmphastar Pharmaceuticals0.793.852.82EPPiShares MSCI Pacific ex Japan ETFN/AN/AN/AINFAInformatica0.732.162.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMPHAmphastar Pharmaceuticals65.09%EPPiShares MSCI Pacific ex Japan ETF74.75%INFAInformatica98.45%Insider OwnershipCompanyInsider OwnershipAMPHAmphastar Pharmaceuticals29.60%EPPiShares MSCI Pacific ex Japan ETFN/AINFAInformatica2.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMPHAmphastar Pharmaceuticals1,97644.09 million31.04 millionOptionableEPPiShares MSCI Pacific ex Japan ETFN/A38.70 millionN/ANot OptionableINFAInformatica5,200308.36 million299.73 millionOptionableEPP, INFA, HGEN, and AMPH HeadlinesRecent News About These CompaniesLike DoorDash and Google’s CEOs, $7.6 billion Informatica boss is a McKinsey alum—he says being ‘pushed around’ by smart consultants helped him growJanuary 17, 2026 | fortune.comInformatica Named a Leader in 2026 Gartner® Magic Quadrant™ for Data & Analytics Governance PlatformsJanuary 9, 2026 | businesswire.comInformatica Inc. (NYSE:INFA) Receives Average Rating of “Reduce†from BrokeragesDecember 26, 2025 | defenseworld.netDInformatica Named a Leader in 2025 Gartner® Magic Quadrant™ for Data Integration Tools for 20 Consecutive YearsDecember 11, 2025 | businesswire.comInvestigation Launched into Informatica Inc., Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm - RGRD LawDecember 10, 2025 | markets.businessinsider.comInvestigation Launched into Informatica Inc., Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm - RGRD LawDecember 10, 2025 | newsfilecorp.comNWhy the timing was right for Salesforce’s $8 billion acquisition of Informatica — and for the opportunities aheadDecember 6, 2025 | fortune.comSalesforce Beats, Raises Outlook — With Informatica Deal Adding BoostDecember 5, 2025 | investors.comSalesforce beats, raises outlook — with Informatica deal adding sparkDecember 4, 2025 | msn.comInformatica Named a Leader in the 2025 Gartner® Magic Quadrant™ for Metadata Management Solutions ReportNovember 21, 2025 | businesswire.comAnalysts Offer Insights on Technology Companies: IonQ (IONQ) and Informatica (INFA)November 20, 2025 | theglobeandmail.comInformatica Terminates Credit Agreement Amidst Corporate ChangesNovember 18, 2025 | tipranks.comSalesforce’s Strategic Acquisition of Informatica: Enhancing Data Management and AI CapabilitiesNovember 18, 2025 | tipranks.comSalesforce Completes Acquisition of InformaticaNovember 18, 2025 | tipranks.comSalesforce Buys Informatica as Clean Data Becomes the Key to Winning the AI RaceNovember 18, 2025 | tipranks.comSTNE vs. INFA: Which Stock Is the Better Value Option?November 14, 2025 | zacks.comSalesforce (NYSE:CRM) to Acquire Spindle AI in Push for Smarter, Autonomous Enterprise SoftwareNovember 10, 2025 | msn.comA Fresh Look at Informatica (INFA) Valuation as Shares Tread WaterNovember 9, 2025 | finance.yahoo.comInformatica’s Strong Q3 2025 Financial PerformanceNovember 5, 2025 | tipranks.comInformatica Inc. (INFA) Tops Q3 Earnings and Revenue EstimatesNovember 5, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEPP, INFA, HGEN, and AMPH Company DescriptionsAmphastar Pharmaceuticals NASDAQ:AMPH$20.16 +0.77 (+3.97%) Closing price 04:00 PM EasternExtended Trading$20.16 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.iShares MSCI Pacific ex Japan ETF NYSEARCA:EPP$53.40 +0.28 (+0.53%) As of 04:10 PM EasterniShares MSCI Pacific ex Japan ET (the Fund), formerly iShares MSCI Pacific ex-Japan Index Fund, is an exchange-traded fund (ETF). The Fund seeks to provide investment results that correspond generally to the price and yield performance of publicly traded securities in the aggregate in the Australia, Hong Kong, New Zealand and Singapore markets, as measured by the MSCI Pacific ex-Japan Index (the Index). The Fund invests in a representative sample of securities that collectively has an investment profile similar to the underlying index. The securities selected are expected to have, in aggregate , investment characteristics, fundamental characteristics and liquidity measures similar to those of the underlying index. The Fund's investment advisor is BlackRock Fund Advisors.Informatica NYSE:INFAInformatica Inc. develops an artificial intelligence-powered platform that connects, manages, and unifies data across multi-vendor, multi-cloud, and hybrid systems at enterprise scale worldwide. Its platform includes a suite of interoperable data management products, including data integration products to ingest, transform, and integrate data; API and application integration products that enable users to create and manage APIs and integration processes for app-to-app synchronization, business process orchestration, B2B partner management, application development, and API management; data quality and observability products to profile, cleanse, standardize, observe, and monitor data to deliver accurate, complete, and consistent data; and master data management products to create an authoritative single source of truth of business-critical data. The company's platform also includes customer and business 360 application that allow business analysts to create 360-degree views of business data domains like customer, product, supplier, reference, and finance with simplified business user experiences; data catalog products that enables customers to quickly find, access, and understand enterprise data using a simple Google-like search experience; governance and privacy products that help users define policies, govern data, and ensure compliance with industry and corporate policies; and a data marketplace that delivers cloud shopping experience for data consumers and enables data sharing and AI models across organizations to facilitate data-driven decision making. It also offers maintenance and professional services. The company sells its products through its direct sales team. The company was founded in 1993 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Corning Is Paving AI's Future With Glass The J.M. Smucker Company’s Dividend: Too Sweet to Ignore? Why's Amazon Suddenly Lagging the S&P 500, and Is It a Warning? Apple's Siri AI Was Finally Announced, So Why Is the Stock Tanking? From Crypto to AI: Insiders Are Trading These 3 Stocks The Case for Intel Over Pure-Play Quantum Firms Has Temu-Owner PDD's Story Changed After Double Miss? Campbell's Soup Stock: Deep Value and a 7% Dividend Yield Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
